Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Venous Thrombosis IV: Nursing Management

Venous Thrombosis IV: Nursing Management

Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Indications for haematopoietic cell transplantation and CAR-T for haematological diseases, solid tumours and immune disorders: 2025 EBMT practice recommendations.

Bone marrow transplantation·2025

Same author

Interconnected pathways link faecal microbiota plasma lipids and brain activity to childhood malnutrition related cognition.

Nature communications·2025

Same author

JAK Inhibitors for Myelofibrosis: Strengths and Limitations.

Current hematologic malignancy reports·2024

Same author

Integrative analysis reveals novel insights into juvenile idiopathic arthritis pathogenesis and shared molecular pathways with associated traits.

Frontiers in genetics·2024

Same author

Response to Letter to Editor: Comment on "The infant gut microbiome and cognitive development in malnutrition".

Clinical nutrition (Edinburgh, Scotland)·2024

Same author

von Willebrand factor antigen, von Willebrand factor propeptide and ADAMTS13 activity in TIA or ischaemic stroke patients changing antiplatelet therapy.

Journal of the neurological sciences·2024

Same journal

Could anticholinergics accelerate ALS progression? A critical perspective on drug safety and disease vulnerability.

Expert opinion on drug safety·2026

Same journal

Safety profile of teprotumumab-trbw, the first and only FDA-approved treatment for thyroid-associated ophthalmopathy.

Expert opinion on drug safety·2026

Same journal

A systematic review and meta-analysis of safety and efficacy parameters of sotatercept in the therapy of pulmonary arterial hypertension.

Expert opinion on drug safety·2026

Same journal

Tirzepatide data: safety first is safety always!

Expert opinion on drug safety·2026

Same journal

An update on the safety of biologics for the treatment of psoriasis.

Expert opinion on drug safety·2026

Same journal

Recent advances in trastuzumab and its antibody-drug conjugates-related liver injury.

Expert opinion on drug safety·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Mar 21, 2026

Busulfan as a Myelosuppressive Agent for Generating Stable High-level Bone Marrow Chimerism in Mice

Busulfan as a Myelosuppressive Agent for Generating Stable High-level Bone Marrow Chimerism in Mice

Published on: April 1, 2015

Safety considerations when treating myelofibrosis.

J M O'Sullivan¹, D P McLornan², C N Harrison¹

¹a Department of Haematology , Guy's and St. Thomas' NHS Foundation Trust, Guy's Hospital , London , UK.

Expert Opinion on Drug Safety

|May 18, 2016

Summary

This summary is machine-generated.

Janus Kinase (JAK) inhibitors like ruxolitinib offer new treatment options for myelofibrosis (MF). While beneficial, careful management is needed for side effects and treatment resistance in MF patients.

Keywords:

JAK inhibitors myelofibrosis ruxolitinib safety

More Related Videos

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis

Published on: August 26, 2025

Related Experiment Videos

Last Updated: Mar 21, 2026

Busulfan as a Myelosuppressive Agent for Generating Stable High-level Bone Marrow Chimerism in Mice

Busulfan as a Myelosuppressive Agent for Generating Stable High-level Bone Marrow Chimerism in Mice

Published on: April 1, 2015

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis

Published on: August 26, 2025

Area of Science:

Hematology
Oncology

Background:

Myelofibrosis (MF) is a clonal disorder characterized by bone marrow fibrosis, cytopenias, and extramedullary hematopoiesis.
Current management strategies for MF are evolving with the advent of targeted therapies.

Purpose of the Study:

To discuss the management of myelofibrosis (MF).
To focus on the efficacy and safety of Janus Kinase (JAK) inhibitors, specifically ruxolitinib.
To review traditional therapies and emerging JAK inhibitors.

Main Methods:

Review of Janus Kinase (JAK)1/JAK 2 inhibitor ruxolitinib's efficacy and safety profile.
Discussion of potential beneficial and detrimental immunosuppressive effects of ruxolitinib.
Overview of traditional MF therapies including hydroxycarbamide, interferon, immunomodulatory drugs, and androgens.

Main Results:

Ruxolitinib demonstrates manageable hematological side effects and significant benefits for symptomatic MF patients.
Other JAK inhibitors like momelotinib show potential for alleviating anemia.
Some JAK inhibitors have faced withdrawal due to toxicities, such as Wernicke's encephalopathy with Fedratinib.

Conclusions:

The introduction of JAK inhibitors has expanded therapeutic options for myelofibrosis.
Ruxolitinib is a valuable treatment for symptomatic MF, but challenges remain for patients with severe thrombocytopenia or those resistant to therapy.
Optimal management strategies are crucial for patients with MF who lose response or are resistant to JAK inhibitors, especially those with high-risk mutations.